Clinical Trials
149 trialsNCT03260894 2026-05-22
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
Incyte Corporation
Phase 3 Completed
NCT02555748 2026-03-31
SUP-R
Institut Claudius Regaud
Phase 4 Completed
NCT01931098 2025-08-11
Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00720941 2025-03-30
COMPARZ
Novartis
Phase 3 Completed
NCT01147822 2025-03-28
Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma
Novartis
Phase 2 Completed
NCT01543763 2025-03-21
Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors
University of California, San Francisco
Phase 1 Completed
NCT01767636 2025-03-03
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer
Mayo Clinic
Phase 2 Completed
NCT02009449 2024-11-15
IVY
Eli Lilly and Company
Phase 1 Completed
NCT02049905 2024-06-13
Phase 3 Study to Treat Patients With Soft Tissue Sarcomas
ImmunityBio, Inc.
Phase 3 Completed
NCT00827372 2023-10-16
A Study of Vascular Endothelial Growth Factor (VEGF) Inhibition in Patients With Unilateral Upper Extremity Lymphedema Following Treatment for Cancer
Indiana University
Phase 2 Completed
NCT02383251 2023-09-06
TAPAZ
ARCAGY/ GINECO GROUP
Phase 2 Completed
NCT03200717 2023-08-21
IO-PAZ
Novartis
Phase 2 Completed
NCT03798106 2023-06-12
A Study of Pazopanib and Durvalumab for Metastatic Soft Tissue Sarcoma
Yonsei University
Phase 2 Completed
NCT01430572 2023-06-06
Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02066285 2023-03-27
Trial of Pazopanib in Patients With Solitary Fibrous Tumor and Extraskeletal Myxoid Chondrosarcoma
Grupo Espanol de Investigacion en Sarcomas
Phase 2 Completed
NCT01330966 2023-03-10
Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma
Emerald Clinical Inc.
Phase 2 Completed
NCT01462630 2022-08-19
Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma
Fox Chase Cancer Center
Phase 2 Completed
NCT01236547 2022-07-19
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01468922 2022-07-01
Pazopanib and ARQ 197 for Advanced Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT02303028 2022-06-28
TOPAZ
The Hospital for Sick Children
Phase 1/2 Completed
NCT02450136 2022-06-15
Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid Tumors
Samsung Medical Center
Phase NA Completed
NCT02691767 2022-06-15
Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid Tumors
Samsung Medical Center
Phase NA Completed
NCT01498458 2022-06-10
PazoX
GBG Forschungs GmbH
Phase 1 Completed
NCT01157091 2022-06-08
Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer
City of Hope Medical Center
Phase 2 Completed
NCT01664182 2022-06-07
Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT02357810 2022-06-07
Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas
Northwestern University
Phase 2 Completed
NCT01566747 2021-12-23
Second-line Pazopanib Renal Cell Carcinoma (RCC) Study. CTRIAL-IE (ICORG) 10-01, V5
Cancer Trials Ireland
Phase 2 Completed
NCT01472081 2021-12-02
Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)
Bristol-Myers Squibb
Phase 1 Completed
NCT01532687 2021-09-27
Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma
OHSU Knight Cancer Institute
Phase 2 Completed
NCT01392183 2021-09-20
Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01465659 2021-08-05
Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery
Northwestern University
Phase 1/2 Completed
NCT01743482 2021-05-14
Pazotest-01
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Completed
NCT02960906 2021-04-26
BIONIKK
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Phase 2 Completed
NCT01636908 2021-04-15
ICK
Amsterdam UMC, location VUmc
Phase NA Completed
NCT01361334 2021-04-08
PAZOPANIB-AML
University Hospital Muenster
Phase 2 Completed
NCT01610206 2021-02-25
A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer
University of Virginia
Phase 2 Completed
NCT00866697 2021-02-16
Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Novartis
Phase 3 Completed
NCT03139331 2021-01-05
PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma
University of California, San Francisco
Phase 1 Completed
NCT01235962 2020-11-23
PROTECT
Novartis
Phase 3 Completed
NCT02138526 2020-10-19
DIET
Radboud University Medical Center
Phase 1 Completed
NCT01956669 2020-08-12
Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors
Novartis
Phase 2 Completed
NCT02300545 2020-08-05
Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy
Washington University School of Medicine
Phase 2 Completed
NCT01692496 2020-07-23
Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial
Grupo Espanol de Investigacion en Sarcomas
Phase 2 Completed
NCT04462445 2020-07-10
PIPELINE
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Completed
NCT01466972 2020-07-08
Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib
University of California, San Francisco
Phase 2 Completed
NCT02187302 2020-05-28
CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)
Lumos Pharma
Phase 2 Completed
NCT01975519 2020-05-20
A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma
Tracon Pharmaceuticals Inc.
Phase 1/2 Completed
NCT02979899 2020-05-12
TAPPAS
Tracon Pharmaceuticals Inc.
Phase 3 Completed
NCT01446809 2020-04-13
Pazopanib Hydrochloride Followed by Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma
University of Washington
Phase NA Completed
NCT01593748 2020-04-06
A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma
Medical University of South Carolina
Phase 2 Completed